Pharmacy

In this part five series, participants give their opinions on which drugs newer to the market in the last 12 months hold the most promise to reducing morbidity and mortality. Participants also shared which drug in the pipeline holds the most promise. MHE's annual pharmacy survey had over 225 respondents. We will be posting the results over the next few days.

In this part four series, participants give their opinions on the biggest driver of specialty drug expenditures this year and what the most significant change in contracts between plan sponsors and PBMs could be in the near future. MHE's annual pharmacy survey had over 225 respondents. We will be posting the results over the next few days.

In this part three series, participants give their opinions on the most effective ways to reduce traditional and specialty pharmaceutical costs. MHE's annual pharmacy survey had over 225 respondents. We will be posting the results over the next several days.

Respondents upbeat about COVID-19 vaccination. MHE's annual pharmacy survey had over 225 respondents. We will be posting the results over the next several days.

Ten years ago, specialty accounted for 15% to 20% of the money spent on drugs, according to Prem Shah, executive vice president of specialty pharmacy and product innovation at CVS Health.

Two of the biggest issues in healthcare, currently, are the lack of communication between prescribers and pharmacists, and the number of factors that prevent healthcare professionals from offering patient-centric services.

PBMs say exclusions are important for negotiating lower prices on behalf of health plans and members. Some payer and provider groups say they interfere with patient access to medicines.

Having specialty pharmacies fill prescriptions may lower costs, but critics of the practice see safety issues and other drawbacks.

Opinion piece by MHE's Editorial Advisory Board Member and CEO of The Pharmacy Group, Perry Cohen. Perry discusses the response differences and vague similarities between the countries and addresses the continuous question, "What is the new normal?"

Health plans build strategies to ensure their beneficiaries have easy access to and receive vital immunizations.

Featured speaker at the 4th Annual PBMI Specialty Rx Forum on October 16 discusses theme of the meeting.

Can data mined from EHRs match that from the gold standard, randomized clinical trials?

The 2020 meeting, presented in a virtual format from its original host city of Amsterdam, The Netherlands, had lots of important science and a record number of viewers.

As it has done with so much else in healthcare, COVID-19 dominated our 2020 annual pharmacy survey. The disease was addressed in 10 of our 13 areas we covered, either within the question itself or as a possible answer. Third of three parts. See more in our Surveys tab.

As it has done with so much else in healthcare, COVID-19 dominated our 2020 annual pharmacy survey. The disease was addressed in 10 of our 13 areas we covered, either within the question itself or as a possible answer. Second of three parts. See more in our Surveys tab.

As it has done with so much else in healthcare, COVID-19 dominated our 2020 annual pharmacy survey. The disease was addressed in 10 of our 13 areas we covered, either within the question itself or as a possible answer. First of three parts. See more in our Surveys tab.

Senior Vice President and Chief Pharmacy Officer for Optum Rx and member of the Managed Healthcare Executive® Editorial Advisory Board, David Calabrese, provides his commentary on the future of pharmacy care services after the coronavirus pandemic.

SingleCare analyzed consumer prescription demand and fill data in the weeks leading up to shelter in place orders, beginning in March, and the subsequent months after the pandemic to see how COVID has impacted the healthcare trends of Americans.

From staffing to readmissions to diagnostics, data intelligence is poised to revolutionize healthcare.

The two PCSK9 inhibitors have fallen far short of expectations. Inclisiran, which works by RNA inference, only needs to be injected twice a year. 

Pharmacy benefit managers are taking steps to be more responsible for the total cost of care and to become more transparent, while adding technology tools to support patients, payers and physicians in a post-COVID-19 world.

Drug makers around the world are racing to develop the first effective COVID-19 vaccine. Early efforts show promise, but an anticipated jump in the novel coronavirus cases in the fall means the sooner a vaccine is developed, the more lives can be saved-and the pharmaceutical industry plays a major role in this discovery.

The Institute for Clinical and Economic Review (ICER) found siponimod has benefits for patients with active secondary progressive multiple sclerosis, but its benefits were in line with other therapies in a crowded marketplace.

Tagrisso, the targeted therapy made by AstraZeneca, could become the treatment of choice for the majority of lung cancer patients with mutations in a certain gene who are treated after surgery, based on findings presented this past weekend at the American Society of Clinical Oncology annual meeting.

He was reluctant to take the CEO job, but VanTrieste has the unique nonprofit drug manufacturer surpassing its goals and possibly branching out into the retail market.

A new study highlights the role a qualified specialty pharmacist can play in driving down costs across a health plan.

A study of patients with inflammatory conditions who were prescribed biologic disease-modifying anti-rheumatic drugs had lower rates of chronic opioid use if they were adherent to their biologic therapy, according to new research.

Taiwan has had only 6 COVID-19-related deaths. The country used community pharmacists to subdue the outbreak.

The opioid epidemic is far from over, but it may slip behind other challenges. COVID-19 obviously tops the list of new problems and drug pricing and affordability will continue to soak up time and attention.